- Home
- CHNR vs ADXN Comparison
CHNR vs ADXN Comparison
Compare CHNR & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- ADXN
- Stock Information
- Founded
- CHNR N/A
- ADXN 2002
- Country
- CHNR China
- ADXN Switzerland
- Employees
- CHNR N/A
- ADXN N/A
- Industry
- CHNR Precious Metals
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- ADXN Health Care
- Exchange
- CHNR Nasdaq
- ADXN Nasdaq
- Market Cap
- CHNR 4.6M
- ADXN 8.1M
- IPO Year
- CHNR 1995
- ADXN N/A
- Fundamental
- Price
- CHNR $3.82
- ADXN $9.20
- Analyst Decision
- CHNR
- ADXN Strong Buy
- Analyst Count
- CHNR 0
- ADXN 1
- Target Price
- CHNR N/A
- ADXN $30.00
- AVG Volume (30 Days)
- CHNR 150.7K
- ADXN 13.1K
- Earning Date
- CHNR 05-15-2025
- ADXN 06-19-2025
- Dividend Yield
- CHNR N/A
- ADXN N/A
- EPS Growth
- CHNR N/A
- ADXN N/A
- EPS
- CHNR N/A
- ADXN 0.10
- Revenue
- CHNR N/A
- ADXN $278,508.00
- Revenue This Year
- CHNR N/A
- ADXN $86.57
- Revenue Next Year
- CHNR N/A
- ADXN N/A
- P/E Ratio
- CHNR N/A
- ADXN $0.76
- Revenue Growth
- CHNR N/A
- ADXN N/A
- 52 Week Low
- CHNR $3.57
- ADXN $6.51
- 52 Week High
- CHNR $9.04
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- CHNR 44.82
- ADXN 60.47
- Support Level
- CHNR $3.66
- ADXN $8.50
- Resistance Level
- CHNR $4.30
- ADXN $9.78
- Average True Range (ATR)
- CHNR 0.67
- ADXN 0.73
- MACD
- CHNR -0.04
- ADXN 0.07
- Stochastic Oscillator
- CHNR 9.64
- ADXN 85.39
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.